LOXL1 and pachyonychia congenita: LOXL1-AS1 is also highly expressed in renal cell carcinoma (RCC) [69], esophageal squamous cell carcinoma (ESCC) [70], thymic carcinoma (TC) [71], pancreatic carcinoma (PC) [72] and endometrial carcinoma (EC) [17], promoting tumor progression.